文献速递肺结节与肺癌间质性肺疾病

肺癌免疫检查点抑制剂相关肺炎:北卡罗来纳六中心真实世界发生率、危险因素与管理实践

Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
PubMed 文献 · Chest · 2021-02-20

基线胸部CT纤维化、阻塞性肺疾病复合指标及帕博利珠单抗治疗与ICI-P独立相关。

要点

  • ICI-P发生率为9.5%,中位诊断时间52.5天,多数为高严重度且27%死亡。
  • 基线胸部CT纤维化使ICI-P风险显著升高(aOR 6.61,95%CI 2.48-17.7)。
  • 阻塞性肺疾病复合指标(aOR 2.79)和帕博利珠单抗治疗(aOR 2.57)亦为独立危险因素。

核心结论

  • 该队列中ICI-P比既往报道更常见且更严重,死亡率出乎意料地高。
  • ICI-P风险与多种慢性肺疾病独立相关,可能解释肺癌患者中ICI-P发生率较高。

研究设计与样本

  • 患者主要接受纳武利尤单抗(76.5%)或帕博利珠单抗(22%)。
  • 对ICI-P患者与对照者进行特征描述,采用逻辑回归评估ICI-P危险因素。

主要发现

  • ICI-P发生率为9.5%,中位诊断时间52.5天。
  • 多数ICI-P患者为高严重度病例,8例(27%)在持续ICI-P治疗中死亡。
  • 基线胸部CT纤维化与ICI-P独立相关(aOR 6.61;95%CI 2.48-17.7)。
  • 阻塞性肺疾病复合指标与ICI-P独立相关(aOR 2.79;95%CI 1.07-7.29)。
  • 帕博利珠单抗治疗与ICI-P独立相关(aOR 2.57;95%CI 1.08-6.11)。

临床怎么用

  • 对接受ICI治疗的肺癌患者,应评估基线胸部CT纤维化及阻塞性肺疾病等慢性肺病以识别ICI-P高危人群。
  • 使用帕博利珠单抗时需警惕ICI-P风险,加强监测与早期识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-small cell lung cancer and have expanded use in small cell lung cancer. Although generally better tolerated than traditional chemotherapy, immune-related adverse events, such as immune checkpoint inhibitor-related pneumonitis (ICI-P), remain poorly understood toxicities that limit ICI treatment and can result in considerable morbidity. In this retrospective case-control study, we assessed a lung cancer cohort to identify ICI-P risk factors. RESEARCH QUESTION: What are the risk factors, clinical presentations, radiographic findings, and outcomes for ICI-P in a real-world lung cancer cohort? Do chronic pulmonary diseases confer increased risk for ICI-P? STUDY DESIGN AND METHODS: Medical records from lung cancer patients receiving nivolumab, pembrolizumab, or combination ipilimumab and nivolumab at six centers in North Carolina were reviewed (January 2004-July 2017). Patients with ICI-P and control participants were characterized, and logistic regression was used to assess for ICI-P risk factors. RESULTS: Three hundred fifteen lung cancer patients who predominantly received nivolumab (76.5%) or pembrolizumab (22%) were included. The incidence of ICI-P was 9.5%, with a median time to diagnosis of 52.5 days. Most patients with ICI-P had cases of high severity, and eight patients (27%) died with ongoing ICI-P treatment. Development of ICI-P was independently associated with the presence of baseline fibrosis on chest CT scan (adjusted OR [aOR], 6.61; 95% CI, 2.48-17.7), a composite measure of obstructive lung disease (aOR, 2.79; 95% CI, 1.07-7.29), and treatment with pembrolizumab (aOR, 2.57; 95% CI, 1.08-6.11). INTERPRETATION: In this cohort, ICI-P was more common and severe than previously reported and carried an unexpectedly high mortality rate. Risk for ICI-P was shown to be independently associated with several chronic pulmonary diseases, which may account for the higher incidence of ICI-P in patients with lung cancer.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021. PMID: 33621599. doi:10.1016/j.chest.2021.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。